Semax vs Selank: nootropic peptide evidence

Semax and Selank are two short synthetic peptides that came out of Soviet and Russian research programs in the 1980s and 1990s. Both are used as nasal sprays, both raise brain-derived neurotrophic factor (BDNF), and both are marketed online as "nootropics," but they were built for very different jobs. This article walks through what each one actually does, what the human evidence really shows, and where that evidence is thin, mixed, or simply hard to check.

The short version is this: Semax leans toward focus, attention, and protecting brain tissue after injury, while Selank leans toward calming anxiety without the fog of a benzodiazepine. Neither is approved by the U.S. Food and Drug Administration (FDA), and most of the human data comes from Russian clinical practice that has never been repeated in large Western trials.

What Semax and Selank are

Both compounds are heptapeptides, meaning each is a chain of seven amino acids. They are tiny molecules compared to a full protein, which is part of why they can be given through the nose and still reach the brain.

Semax has the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is a modified fragment of a natural hormone called adrenocorticotropic hormone (ACTH), specifically the ACTH(4-7) region, with a short Pro-Gly-Pro tail added on to slow its breakdown. That tail matters. Plain ACTH fragments fall apart in seconds, but the added amino acids let Semax last long enough to act. Importantly, Semax keeps the brain and behavior effects of ACTH while dropping the hormonal ones, so it does not crank up cortisol the way the full hormone would.

Selank has the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is a modified version of a natural immune peptide called tuftsin (Thr-Lys-Pro-Arg), again with a Pro-Gly-Pro tail bolted on for stability. Tuftsin started life as an immune-system molecule, so Selank carries some immune-modulating activity along with its effects on mood and anxiety.

Both were developed largely at Russian institutes, including the Institute of Molecular Genetics of the Russian Academy of Sciences and the Zakusov Institute of Pharmacology. Both are sold in Russia as registered nasal-spray drugs. In the United States and most of the West, neither is approved, and they circulate as compounded prescriptions or as "research chemicals."

How each one works in the brain

This is where the two peptides start to split. They share one headline mechanism, BDNF, but the rest of the picture differs.

Semax: attention, dopamine, and neuroprotection

Semax's most studied effect is a fast rise in BDNF and its partner receptor TrkB, mostly in the hippocampus, the brain region tied to memory. BDNF is a growth factor that helps neurons survive, form new connections, and stay flexible. In rat studies, Semax also bumps up nerve growth factor (NGF). One peer-reviewed analysis showed that Semax and its breakdown fragment Pro-Gly-Pro both switch on the genes for these neurotrophins and their receptors after a stroke-like injury, which lines up with the idea that part of the benefit comes from gene-level changes, not just a quick chemical bump.

On top of the growth-factor story, Semax nudges the dopamine and serotonin systems in the front of the brain. That is the most likely reason users report sharper focus, more drive, and steadier attention rather than just a sense of calm. Because it traces back to an ACTH fragment, Semax also touches the brain's attention and alertness circuits that ACTH normally helps run.

Selank: GABA, enkephalins, and calm without sedation

Selank's main job is to take the edge off anxiety. It does this in a way that looks different from a benzodiazepine like Xanax or Valium. Those drugs grab onto a specific "benzodiazepine site" on the GABA-A receptor, and that binding is what brings the sedation, the memory gaps, and the dependence. Selank does not appear to bind that site. Instead it seems to raise GABA tone through a separate route, which may explain why Russian data describe calm without heavy drowsiness.

Selank has a second trick that benzodiazepines lack. It slows down the enzymes that break apart enkephalins, the body's own opioid-like "feel okay" peptides. A peer-reviewed study found that Selank blocks these enkephalin-degrading enzymes in human blood serum, which would let your natural enkephalins hang around longer and may contribute to the anti-anxiety effect. Like Semax, Selank also raises BDNF; a controlled animal study showed that intranasal Selank increased BDNF messenger RNA within hours and BDNF protein within a day in the rat hippocampus.

Mechanism at a glance

Feature	Semax	Selank
Parent molecule	ACTH(4-7) fragment	Tuftsin (an immune peptide)
Amino acid sequence	Met-Glu-His-Phe-Pro-Gly-Pro	Thr-Lys-Pro-Arg-Pro-Gly-Pro
Headline effect	Focus, attention, neuroprotection	Anti-anxiety, calm
Shared mechanism	Raises BDNF and TrkB	Raises BDNF
Distinct mechanism	Boosts dopamine and serotonin signaling	Modulates GABA tone (not at the benzo site); slows enkephalin breakdown
Hormonal effect	None of ACTH's hormonal action	Some immune-modulating activity from tuftsin
Best-supported clinical use (Russia)	Ischemic stroke recovery	Generalized anxiety and neurasthenia

The actual human evidence, graded honestly

Here is the part that most marketing pages skip. The mechanism studies above are real and reasonably solid, mostly in rats. The human evidence is a different story: it exists, but it is thin, often small, frequently published only in Russian, and almost never repeated by independent Western groups. Below is an honest grade, study by claim.

Semax for ischemic stroke: the strongest case, but still regional

The best human evidence for either peptide is Semax in acute ischemic stroke. Russian clinical work has reported faster neurological recovery and better function when Semax is given in the acute phase. One clinical study tracked stroke patients on a standard regimen and found that Semax raised plasma BDNF levels, which stayed elevated through the study, and that higher BDNF tracked with faster gains on the Barthel Index, a basic measure of daily independence. Semax is on Russia's list of essential medicines for stroke.

The honest caveat: these are moderate-sized Russian trials, and the gold-standard test, a large multicenter randomized double-blind trial run by a group with no stake in the drug, has not been published in the West. A 2023 peer-reviewed review of neuroprotective peptides for stroke groups Semax with other compounds that show promise in lab models but lack the large confirmatory human trials that change Western practice. It is also worth being clear about what "stroke recovery" evidence does and does not say about a healthy brain. A drug that protects injured neurons after a clot is not automatically a drug that makes a healthy brain sharper. The biology of a damaged, oxygen-starved brain is different from the biology of a rested, well-fed one, so the stroke data, even at its best, cannot be borrowed to justify daily focus use. Grade: moderate evidence, real but unreplicated outside Russia, and specific to injury rather than enhancement.

Semax for healthy-person "nootropic" use: weak and oversold

The claim that Semax sharpens a healthy person's focus rests largely on a 1996 study by Kaplan and colleagues, which reported that intranasal Semax improved attention and short-term memory in human volunteers and produced EEG changes like those seen with standard nootropic drugs. The signal is interesting, but it is one small study, decades old, and published in a journal not indexed in PubMed, so it is hard to scrutinize. There is no large, modern, placebo-controlled trial in healthy adults that confirms a meaningful cognitive boost. Grade: weak. Plausible, not proven.

Selank for anxiety: a single comparison trial does the heavy lifting

Selank's reputation for anxiety relief leans heavily on a 2008 Russian comparison trial led by Zozulia and colleagues. It enrolled roughly 60 patients with generalized anxiety disorder and neurasthenia, comparing Selank against the benzodiazepine medazepam. The authors reported that Selank's anti-anxiety effect was similar to the benzodiazepine on the Hamilton, Zung, and Clinical Global Impression scales, with extra anti-fatigue benefits and no notable side effects. That is a genuinely useful finding.

The honest caveat: it is one trial, with about 30 people in the Selank arm, run by the institutions tied to the drug's development, and it was not a large double-blind Western study. The "comparable to a benzodiazepine, no dependence, no withdrawal" claim you see everywhere online traces back to this small body of work, not to a deep stack of independent trials. Grade: weak-to-moderate. Promising direction, thin and non-independent evidence.

Evidence summary

Claim	Strength of human evidence	Honest note
Semax speeds ischemic stroke recovery	Moderate	Real Russian trials; no large Western RCT
Semax boosts cognition in healthy people	Weak	One small old study; no modern placebo trial
Selank reduces anxiety	Weak to moderate	Mainly one ~60-patient trial by the developers
Selank causes no dependence or withdrawal	Weak	Reported in Russian data; not independently confirmed
Either peptide raises BDNF	Moderate	Solid in animals; less direct in humans
Long-term safety in humans	Very weak	No long-term controlled safety studies published

A fair bottom line: the mechanisms are believable and the early human signals point the right way, but the depth, scale, and independent replication that Western medicine demands are missing. These are best called "plausible and promising," not "established."

It helps to understand why the evidence stays stuck at this level. Both peptides were developed by the same handful of Russian institutes that then ran most of the trials. That is not proof the results are wrong, but it is exactly the setup where independent replication matters most, because a developer has every incentive to see a positive result. Add the language barrier, since much of the literature exists only in Russian or as short English abstracts, and the small sample sizes, and you get a body of work that is genuinely hard for an outside reviewer to weigh. The deeper problem is not that nobody has studied these peptides. A PubMed search for Semax returns well over a hundred papers. The problem is that the studies are mostly small, mechanistic, animal-based, or produced by the same research lineage, so the pile is wide but shallow where it counts: large, blinded, independent human trials.

Semax vs Selank: which fits which goal

Because the two peptides pull in different directions, the comparison is less "which is better" and more "which problem are you trying to solve."

Choose Semax if the goal is focus, mental drive, or recovery support after a brain insult. Its dopamine and attention effects make it the more "stimulating" of the two, and its strongest evidence sits in stroke recovery. Some people stack a low dose into a morning routine for focus, though, again, the healthy-person cognition evidence is weak.

Choose Selank if the goal is calmer baseline anxiety without sedation. Its profile is the gentler, more "anti-stress" one. People who get jittery on stimulants sometimes prefer it for that reason.

Many users combine the two, using Semax for daytime focus and Selank to soften the overstimulation or anxiety that can come with it. There is no robust trial proving the combination is safe or better than either alone; the pairing is based on mechanism and anecdote, not data. If you are exploring how peptides get combined in general, our peptide stacking guide covers the broader logic and the real risks of layering compounds.

Dosing as reported in the literature (not a recommendation)

The doses below reflect what shows up in Russian clinical reports and product labeling. They are presented for understanding the research, not as instructions. Neither peptide is FDA-approved, and self-dosing an unapproved drug carries real risk.

Parameter	Semax	Selank
Common form	Intranasal solution (0.1% or 1%)	Intranasal solution (0.15%)
Typical reported dose	~200-600 mcg/day for focus; up to 6,000 mcg/day in stroke protocols	~300-900 mcg/day, often split
Onset	Within an hour	Within an hour
Course length in trials	10-day courses, sometimes repeated	About 14 days
Main reported use	Focus, stroke recovery	Anxiety, fatigue

The wide gap in Semax dosing is worth flagging: a focus "microdose" and a hospital stroke protocol differ by an order of magnitude, and the high-dose data come from supervised medical settings, not home use. For how peptides are mixed and measured from powder, see our peptide reconstitution guide.

Safety, side effects, and the big unknowns

In the Russian human studies, both peptides come across as well tolerated over short courses. Reported side effects are usually mild: nasal irritation, a brief headache, occasional trouble sleeping if dosed late (more an issue with the stimulating Semax). Selank's calm-without-sedation profile is one of its main selling points, and the available data do not show the dependence or rebound anxiety seen with benzodiazepines.

But the safety picture has real holes:

No long-term human safety data. The trials are short. We do not have controlled studies following users for months or years, so chronic effects are genuinely unknown.
Quality and purity vary wildly. Most peptides bought online are sold "for research only," with no guarantee of identity, dose accuracy, or sterility. A nasal product made in an unregulated lab can carry contaminants. If you are evaluating sellers, our peptide vendor quality standards guide lays out what third-party testing should actually show.
BDNF effects cut both ways. Raising a growth factor sounds purely good, but growth signals interact with conditions like cancer in ways that are not mapped out for these peptides. People with a relevant history should be especially cautious.
Drug interactions are understudied. How these peptides behave alongside antidepressants, stimulants, or anxiety medications has not been carefully tested in humans.

People who are pregnant or breastfeeding, who have a serious psychiatric or neurological condition, or who take other central-nervous-system drugs should not experiment here without a knowledgeable physician.

How they compare with other options

Semax and Selank are not the only paths to focus or calm, and in many cases they are not the best-supported.

For anxiety, the treatments with deep, independent, controlled evidence are still SSRIs, SNRIs, cognitive behavioral therapy, and, for short-term use, benzodiazepines. Selank's appeal is the promise of benzodiazepine-like relief without dependence, but that promise rests on far less data than the standard treatments carry.

For focus and cognition, the honest comparison is humbling. Sleep, exercise, and treating an underlying condition like ADHD with proven medication will out-perform any nootropic peptide in the evidence column. Among supplements, even well-studied options have modest effects. Semax may help, but it has not been shown to beat these basics in a healthy person.

Within the peptide world, several other compounds get marketed for the brain. A few have research worth reading on their own terms, including N-acetyl Semax amidate, a longer-acting Semax variant; the synaptic peptide studied in FGL peptide cognitive research; and the memory-linked work covered in vasopressin cognitive peptide research. None of these has Western-grade clinical proof either, so the same caution applies.

Who each one is realistically for

Semax and Selank sit in a gray zone. They are not snake oil; there is real mechanism and real, if limited, human data behind them. But they are also not validated medicines in the United States, and the gap between online claims and proven results is wide.

Semax may interest someone exploring focus support or, in a medical setting abroad, stroke rehabilitation. Selank may interest someone looking for non-sedating anxiety relief who understands the evidence is thin. In both cases, the realistic expectation is a modest, individual-dependent effect, not a dramatic transformation.

The people these are clearly not for: anyone hoping to skip proven treatment for a real anxiety disorder, anyone expecting a guaranteed cognitive edge, anyone who cannot verify the quality of what they are buying, and anyone unwilling to involve a doctor. For a structured way to start any peptide safely, our how to start peptide therapy guide is a better first stop than any vendor's sales page.

Frequently Asked Questions

Is Semax or Selank approved by the FDA?

No. As of 2026, neither Semax nor Selank is FDA-approved for any use in the United States. Both are registered drugs in Russia but are treated as unapproved compounds in the U.S. They may be available through compounding pharmacies under specific rules, but compounded drugs are not FDA-approved and their oversight is limited. The regulatory status of these peptides has been shifting, so it is worth checking current FDA compounding guidance before assuming a product is legitimate.

What is the main difference between Semax and Selank?

Semax is geared toward focus, attention, and neuroprotection, working through dopamine, serotonin, and BDNF pathways. Selank is geared toward reducing anxiety without sedation, working through GABA tone, enkephalin preservation, and BDNF. In plain terms, Semax is the more activating one and Selank is the more calming one.

Can you take Semax and Selank together?

Some users combine them, using Semax for daytime focus and Selank to blunt the overstimulation or anxiety it can cause. This pairing is based on how the two peptides work, plus user anecdote, not on controlled trials. There is no published human study showing the combination is safe or more effective than either alone, so anyone trying it is essentially self-experimenting.

How strong is the evidence that these peptides actually work?

It is mixed and mostly weak by Western standards. The strongest case is Semax for acute ischemic stroke, backed by moderate-sized Russian trials. Selank's anxiety benefit rests largely on a single comparison study of about 60 people run by the drug's developers. Mechanistic animal data are reasonably solid, but large, independent, placebo-controlled human trials are missing for nearly every claim.

Are there side effects or safety risks?

Short-term Russian data describe mild side effects like nasal irritation, headache, or trouble sleeping (more with Semax). The bigger concerns are the unknowns: no long-term human safety studies, highly variable product quality from unregulated sellers, possible interactions with other brain-active drugs, and the general uncertainty of raising a growth factor like BDNF. These are reasons to involve a physician rather than self-treat.

This article is for general information only and is not medical advice. Semax and Selank are not FDA-approved. Talk with a licensed healthcare provider before using any peptide or making changes to your health regimen.